This study is testing an investigational drug called sabirnetug to see if it can slow down the worsening of memory and daily function in people with early Alzheimer's disease. About 542 participants will receive either the drug or a placebo as a monthly intravenous infusion. The …
Phase: PHASE2 • Sponsor: Acumen Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC